tiprankstipranks
Trending News
More News >
Aptose Biosciences (TSE:APS)
TSX:APS

Aptose Biosciences (APS) AI Stock Analysis

Compare
145 Followers

Top Page

TS

Aptose Biosciences

(TSX:APS)

Rating:37Underperform
Price Target:
Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock's weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.
Positive Factors
Clinical Progress
Aptose has made progress in progressing tuspetinib in the clinic, including initiating and reporting early safety and efficacy data from TUSCANY, a Phase 1/2 triplet combo study in newly diagnosed acute myeloid leukemia.
Financial Stability
The company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.
Partnerships
Aptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement designed to provide necessary additional funding and accelerate clinical development.
Negative Factors
Funding Uncertainty
Aptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.
Market Competition
The TUSCANY trial could position TUS as a promising combination therapy for larger AML populations, avoiding the toxicities observed with other agents.

Aptose Biosciences (APS) vs. iShares MSCI Canada ETF (EWC)

Aptose Biosciences Business Overview & Revenue Model

Company DescriptionAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
How the Company Makes MoneyAptose Biosciences generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company seeks to monetize its innovations through strategic partnerships with larger pharmaceutical companies, licensing agreements, and eventual sales of approved therapeutics. Revenue streams may include upfront payments, milestone payments, royalties on product sales, and research and development funding from partners. As a clinical-stage company, Aptose's financial performance heavily depends on the successful clinical development, regulatory approval, and commercialization of its drug candidates.

Aptose Biosciences Financial Statement Overview

Summary
Aptose Biosciences exhibits significant financial challenges with no revenue and substantial losses. The company's negative equity and high liabilities further emphasize its financial instability. Cash flow is negative, indicating cash burn, although financing activities provide temporary liquidity.
Income Statement
10
Very Negative
Aptose Biosciences has consistently reported zero revenue over the analyzed periods, with significant negative EBIT and net income, indicating high operational losses. The lack of revenue growth and persistent negative profit margins suggest substantial challenges in generating income and controlling expenses.
Balance Sheet
20
Very Negative
The company's balance sheet shows negative stockholders' equity and high liabilities relative to assets, signaling financial instability and high leverage. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities pose a risk. The negative equity ratio further highlights the company's financial distress.
Cash Flow
25
Negative
Aptose Biosciences exhibits negative operating and free cash flows, reflecting cash burn without revenue generation. The free cash flow to net income ratio is unfavorable due to negative values, and the operating cash flow further indicates cash inefficiency, though financing activities provide temporary liquidity support.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-117.97K0.00-474.55K-507.08K-616.53K-646.43K
EBITDA-20.71M0.00-52.27M-42.48M-65.30M-55.62M
Net Income-21.33M-25.43M-51.21M-41.82M-65.35M-55.24M
Balance Sheet
Total Assets7.47M10.13M12.99M51.03M82.53M126.26M
Cash, Cash Equivalents and Short-Term Investments4.70M6.15M9.25M46.96M79.13M122.39M
Total Debt8.98M621.00K1.01M1.30M574.00K1.07M
Total Liabilities14.86M14.67M15.89M13.29M8.29M7.35M
Stockholders Equity-7.39M-4.54M-2.90M37.74M74.24M118.92M
Cash Flow
Free Cash Flow-27.01M-35.98M-44.62M-32.35M-43.52M-33.97M
Operating Cash Flow-27.01M-35.98M-44.59M-32.32M-43.30M-33.89M
Investing Cash Flow2.01M18.00K9.96M30.07M-35.21M12.63M
Financing Cash Flow22.40M33.41M6.91M116.00K226.00K58.81M

Aptose Biosciences Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.09
Price Trends
50DMA
2.33
Negative
100DMA
3.77
Negative
200DMA
7.96
Negative
Market Momentum
MACD
-0.40
Positive
RSI
25.24
Positive
STOCH
6.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APS, the sentiment is Negative. The current price of 1.09 is below the 20-day moving average (MA) of 1.88, below the 50-day MA of 2.33, and below the 200-day MA of 7.96, indicating a bearish trend. The MACD of -0.40 indicates Positive momentum. The RSI at 25.24 is Positive, neither overbought nor oversold. The STOCH value of 6.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:APS.

Aptose Biosciences Risk Analysis

Aptose Biosciences disclosed 49 risk factors in its most recent earnings report. Aptose Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aptose Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
48
Neutral
AU$2.43B4.28-64.25%2.88%35.15%13.63%
TSAPS
37
Underperform
$2.78M391.94%79.63%
36
Underperform
C$4.89M-38.24%-22.96%
C$6.83M
TSTBP
$8.47M
$7.44M
TSRKV
C$13.94M-203.41%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:APS
Aptose Biosciences
1.09
-29.81
-96.47%
TSE:XRTX
XORTX Therapeutics Inc
1.29
-1.15
-47.13%
TSE:COOL
Core One Labs
0.14
-0.04
-22.22%
TSE:TBP
Tetra Bio-Pharma
0.02
0.00
0.00%
BVAXF
BioVaxys Technology
0.03
-0.02
-40.00%
TSE:RKV
Rakovina Therapeutics Inc
0.66
-0.44
-40.00%

Aptose Biosciences Corporate Events

Product-Related AnnouncementsPrivate Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
Aptose Biosciences Advances AML Therapy and Strengthens Financial Position
Positive
Mar 28, 2025

Aptose Biosciences has reported its year-end 2024 results and highlighted significant advancements in its tuspetinib-based triple drug therapy for AML. The ongoing TUSCANY clinical trial has shown promising results, achieving complete remissions in difficult-to-treat AML patients. The company has also signed a debt conversion agreement with Hanmi Pharmaceutical and entered a cooperative research agreement with the National Cancer Institute to further develop tuspetinib. These developments are expected to enhance Aptose’s position in the oncology market and provide additional funding for its clinical programs.

Product-Related AnnouncementsBusiness Operations and Strategy
Promising Early Results from Aptose’s TUSCANY Trial in AML Treatment
Positive
Feb 12, 2025

Aptose Biosciences has reported promising early results from their TUSCANY trial, involving the TUS+VEN+AZA triplet therapy for newly diagnosed AML patients. The trial, which uses a combination of tuspetinib, venetoclax, and azacitidine, has shown complete remissions in patients with TP53-mutated and FLT3-wildtype AML, demonstrating favorable safety and efficacy. These results indicate a potential new frontline treatment for a diverse group of AML patients, enhancing Aptose’s position in the oncology field and offering hope for stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2025